ArticleBioMed research international2017
Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors.
Article in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Risk factors associated with adverse metabolic health in youth with perinatally acquired HIV living in the United Kingdom.AIDS (London, England) · 2026Observational
- High prevalence of impaired glucose metabolism among children and adolescents living with HIV in Ghana.HIV medicine · 2024Article
- HIV-Infected Patients as a Model of Aging.Microbiology spectrum · 2023Article
- Dyslipidemia and Nutritional Status of HIV-Infected Children and Adolescents on Antiretroviral Treatment at the Comprehensive Chronic Care and Training Center of Jimma Medical Center.HIV/AIDS (Auckland, N.Z.) · 2023Article
- Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy.PloS one · 2022Article
- Impaired fasting glucose levels among perinatally HIV-infected adolescents and youths in Dar es Salaam, Tanzania.Frontiers in endocrinology · 2022Article
- Cardiometabolic Complications in Youth With Perinatally Acquired HIV in the Era of Antiretroviral Therapy.Current HIV/AIDS reports · 2021Review
- FGF21 serum levels are related to insulin resistance, metabolic changes and obesity in Mexican people living with HIV (PLWH).PloS one · 2021Article
- Correlates of fasting blood glucose among children living with hiv in a Nigerian tertiary hospital: a cross-sectional study.BMC pediatrics · 2020Article
- Review
- Metabolic syndrome, biochemical markers, and body composition in youth living with perinatal HIV infection on antiretroviral treatment.PloS one · 2020Article
- Recommended First-Line Antiretroviral Therapy Regimens and Risk of Diabetes Mellitus in HIV-Infected Adults in Resource-Limited Settings.Open forum infectious diseases · 2019Article
- Dietary patterns and metabolic morbidities correlate among adolescents and young adults with HIV in Lagos, Nigeria: A cross-sectional study design.Journal of multimorbidity and comorbidityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protease inhibitor (PI) may cause abnormal glucose metabolism, abnormal lipid metabolism, and metabolic syndrome in HIV-infected adults but less well studied in Asian adolescents. This cross-sectional study evaluated anthropometric factors, oral glucose tolerance test, and lipid profiles of perinatally HIV-infected Thai adolescents who had received PI-based antiretroviral therapy for at least 6 months. Eighty adolescents were enrolled [median (IQR) age 16.7 (14.6-18.0) years, 42 males]. Metabolic syndrome, prediabetes, and type 2 diabetes mellitus (T2DM) were found in 8 (10%), 17 (22.1%), and 3 (3.8%) adolescents, respectively. Dyslipidemia was found in 56 (70%) adolescents, with hypertriglyceridemia being the most common type. In multivariate analysis, presence of lipohypertrophy (OR: 25.7, 95% CI: 3.2-202.8;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.